Other infectious disease experience
- Payer and pricing research and landscape analysis of hygiene product reimbursement and funding flow in UK hospitals for hospital acquired infections
- HEOR team capabilities audit and training plan in infectious diseases
- Literature review and development of a suite of dossiers in anti-infectives (anti-bacterial resistance)
- Development of an e-v@luate EVIDENCE platform for a vaccines portfolio
- Literature review of antibiotic resistance
- Cost effectiveness analysis model for Portugal on a treatment for bacterial diabetic foot infections
- Suite of dossiers for an anti-infective in gram-negative infections
- Cost-effectiveness model for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients
- Pharmacoeconomic and PRO design and analysis for an immunoglobulin product
- Analysis in an EU study in primary immunodeficiency
- Pricing reimbursement overview for the UK for a novel anti-viral treatment
- Cost effectiveness model on a treatment for bacterial infections
- Cost-effectiveness analysis of a treatment of intra-abdominal infections in the USA
- Global value dossier, slide deck and FAQs on antibiotic resistance in gram-negative infections
- Update to an anti-infectives dossier in gram negative bacterial infections
- Estimating the return on investment from investing in adult immunisation in Europe
- Strategic access objectives in infectious diseases
- Development of a manuscript and consultation on economic evaluations alongside a clinical trial in intra-abdominal infections
- Structured literature review and value strategic insight to understand the prevalence and burden of vaccine-preventable diseases (haemophilus influenzae, hepatitis A & B, HPV-associated cancers, influenza, measles, mumps, rubella, meningococcal disease, pneumonia, tetanus, diphtheria, whooping cough, chicken pox, and shingles) amongst sub-populations identified in the ACIP recommendations
- Protocol, CRF and distress diary development in infectious diseases
- COA consultancy support and validation of a nasal congestion scale